1 4 9 9 r e v i e w ASDs are defined by deficits in social communication, impaired language development, and the presence of highly restricted interests and/or stereotyped repetitive behaviors. As with all common neuropsychiatric conditions, the reliance on syndromic diagnoses is a consequence of a lack of a better alternative given a very limited understanding of underlying pathology. However, recent successes in both the genetics and genomics of ASDs are promising to change this equation and, along with the rapid pace of related neurobiological studies, are now allowing for a data-driven re-conceptualization of gene-brain-behavior relationships. This progress is already challenging long-standing dogma regarding the nature of the genetic variation contributing to ASDs and is further calling into question the adequacy of the current psychiatric diagnostic nosology.
The conundrums of understanding genetic risks for autism spectrum disorders Matthew W State 1 & Pat Levitt 2 Recent advances in the genetics of autism spectrum disorders (ASDs) are offering new valuable insights into molecular and cellular mechanisms of pathology. At the same time, the emerging data challenge long-standing diagnostic conventions and the notion of phenotypic specificity. This review addresses the particular issues that attend gene discovery in neuropsychiatric and neurodevelopmental disorders and ASDs in particular, summarizes recent findings in human genetics broadly that are driving the reevaluation of the conventional wisdom regarding the allelic architecture of common psychiatric conditions, reviews selected discoveries in ASDs and their relevance to models of pathology, highlights the conceptual and practical issues raised by the observation of a convergence of ASD genetic risks with distinct psychiatric disorders, and considers the important interplay of studies of neurobiology and genetics in clarifying and extending our understanding of social disability syndromes.
r e v i e w that may be very frequently observed clinically, such as gastrointestinal complaints, seizure or sleep disorders in children with ASDs 4 , do not presently contribute to categorical diagnosis. Whether these co-occurring conditions represent features that could distinguish subsets of affected individuals in genetically meaningful ways remains understudied but may well be the case 5 , as discussed below.
Emerging views of the genetic architecture of ASD Challenges aside, the last several years of investigation have resulted in the identification of specific alleles contributing to these syndromes (see recent reviews in refs. 4, 6, 7) . As these hard won successes begin to shed light on pathogenic mechanisms, they also have prompted a reappraisal of the conventional wisdom regarding the nature of the variants that are likely to contribute to ASDs and the predictability of the relationship between genetic variation and brain function and dysfunction.
For several decades, the predominant theory in psychiatric genetics generally has been the common disease-common variant hypothesis: namely, that the majority of the risk for neuropsychiatric disorders will be found in a conspiracy of common alleles (>5% allele frequency), each conferring modest risk, either for the overall phenotype or for subcomponents of a complex presentation [8] [9] [10] . However, despite both the intuitive attractiveness of the hypothesis and feasibility of undertaking case-control studies to search for associated common alleles in or near candidate genes, such approaches have struggled to provide replicable results for any common psychiatric condition.
The fairly recent development of unbiased genome-wide association approaches, facilitated by the emergence of microarray technology, has changed this equation for much of medicine and is now being applied with some success to neuropsychiatric disorders. Notably, a host of reproducible results in other clinical areas, ranging from diabetes to inflammatory bowel disease to intracranial aneurysm, have provided important insights into the reasons for earlier difficulties 11 : Initial cohorts were markedly underpowered as a result of an overestimation of allelic effect sizes; the prior probability of choosing one or a small number of common alleles correctly from among the several million in the genome was fleetingly small, and genetic case-control studies were, and remain, highly sensitive to cryptic sources of mismatch, including for ancestry. Moreover, when viewed cumulatively, the common risk alleles reproducibly identified by genome-wide association studies have, in most instances, accounted for only a small fraction of the anticipated risk for common conditions. This has led to a preoccupation with 'missing heritability' in complex disorders [12] [13] [14] , attributed variously to a combination of an initial overestimation of the contribution of genetics, the involvement of hundreds to thousands of common risk variants of extremely small effect, and/or a substantial role for alleles that are either rare (minor allele frequency (MAF) <5%) or very rare (MAF < 1%) 15 in the population.
Indeed the potential contribution of rare genetic variation has garnered tremendous interest of late, driven by both the experience with GWAS and new genomic technologies, including next generation sequencing, that make the investigation of low-frequency alleles on a genome-wide scale increasingly feasible. In practice, the search for rare variants in common disease typically focuses on one or both of two strategies: identifying extremely rare, Mendelian examples of common disorders and/or investigating the cumulative contribution of rare mutation to common phenotypes. The driving rationale for the former is that gene discovery, even in the rarest examples, has the potential to illuminate key molecular and cellular mechanisms leading, in turn, to new opportunities for intervention. The latter seeks to account for a substantial proportion of population risk, based on the notion that individually rare alleles, given a sufficiently high degree of genetic heterogeneity, may account for most or all of the risk for commonly occurring illnesses.
The notion that rare mutations may underlie a common syndrome such as ASD may at first blush seem counterintuitive, but a number of considerations would suggest otherwise. First, purifying selection would indeed be expected to drive down the population frequency of highly deleterious transmitted alleles, particularly for early onset conditions that affect reproductive fitness (Fig. 1) . In this context, one might also expect a substantial number of sporadic cases to result from de novo mutation, something that is well described in the ASD literature [16] [17] [18] [19] [20] [21] [22] . Clearly, if rare variants were to account for a substantial portion of the risk for ASDs, the number of potential gene targets across the genome would be expected to be large, but would also be expected to converge on a coherent set of biological processes. In support of this, the structural variation and single gene mutations identified thus far have pointed to convergent neurodevelopment and molecular pathways (discussed below), and no single recurrent variation has so far been found in more than about 1% of the affected population.
Rare and common alleles in ASDs
In fact, although the common and rare variant perspectives have tended to be offered as stark counterpoints, evidence suggests that both are likely to contribute to risk and, given the rudimentary understanding of pathophysiology of ASDs, both have clear potential to offer new and important insights. r e v i e w of one or several common alleles in or near these loci. As was the case for almost every common condition studied, the majority of the resulting findings did not replicate convincingly. In ASDs, only a handful of common variants identified in this pre-GWAS era yielded solid evidence for association through studies in large samples, independent replications, and the demonstration of alleles influencing gene expression and/or protein function. However, two findings in particular, involving regulatory single-nucleotide polymorphisms (SNPs) in the receptor tyrosine kinase MET [23] [24] [25] and SNPs mapping to the interval corresponding to the Contactin-associated protein 2 (CNTNAP2) gene 26, 27 (discussed below) continue to generate considerable interest. Family cohort and case-control studies [23] [24] [25] 28 have reported ASDassociated variants in MET, a gene encoding a tyrosine kinase receptor that promotes neuronal growth and synaptogenesis [29] [30] [31] . Three different 5′ regulatory alleles and deletion copy number variants (CNVs) in three individuals have been identified that are not seen in controls (for a review, see ref. 32 ). Moreover, MET signals through the same intracellular pathway containing mutations in other genes implicated in idiopathic and syndromic ASD 28, 33, 34 . The initially characterized MET promoter allele is functional, causing a 50% reduction in gene transcription 24 . Met expression at synapses peaks during their formation and is limited to forebrain limbic and neocortical structures involved in emotional and social behavior regulation 35, 36 . Consistent with these findings, recent studies of functional deletion of Met in the mouse have revealed altered cortical dendrite and spines 29 and a functional phenotype implicated in ASD 37 , electrophysiologically defined local hyperconnectivity 38 .
Yet even with this convergent data, interpretive challenges remain. For example, a substantial association of MET has not yet been identified in any of the three published GWAS studies of ASDs. However, as discussed below, there have been no common risk variants significantly associated with ASDs in more than a single genome-wide study. It is possible that the MET results reflect a false positive finding (type 1 error), but this seems unlikely given independent replication of the functional allele in multiple (but not all) cohorts (reviewed in ref. 32) , altered transcript and protein expression in independent ASD samples of postmortem tissue 39, 40 , and neurobiological evidence for relevance in forebrain circuit development 29, 38 . Another likely alternative is that the lack of agreement across studies reflects patient cohorts that remain markedly underpowered to detect common variants with now-plausible effect sizes in ASD 41 . Moreover, in the case of MET, it is noteworthy that once the first functional risk variant was found to be associated with ASD, further analyses revealed that the allele was enriched in multiplex compared with simplex families and in affected individuals who also exhibit co-occurring gastro-intestinal conditions 5 , a common clinical problem in individuals with ASDs 42 . In this regard, it is important to recall that common functional variants are likely to be modulators of ASD-relevant phenotypes, not disorder-causing per se. Simply stated, some of these alleles may be disorder associated only in certain subpopulations, and there is likely to be a diversity of common alleles influencing the trajectories of disorderrelevant phenotypes apart from categorical diagnoses.
These observations suggest that genetic mechanisms through which associations occur may help to redefine and stratify disorders by exhibiting enrichment in subgroups with a common diagnosis, but with distinguishing phenotypic features. However, this possibility must be viewed simultaneously with the strong evidence that specific genetic risks for ASDs also lead to highly divergent, non-overlapping clinical phenomena 43, 44 . This renders the task of identifying, a priori, component phenotypes that will enhance genetic homogeneity sufficiently to drive gene discovery efforts extremely challenging. It suggests that the more likely and productive scenario will involve hypothesis-driven investigations undertaken subsequent to a definitively established relationship between a particular gene, variation, or molecular pathway and ASD.
As noted, the shift from candidate gene to genome-wide studies of association has been accompanied by an increasingly sophisticated appreciation of the plausible effect sizes of common alleles, an attendant focus on large cohorts, and careful attention to and correction for confounds including occult differences in ancestry among cases and controls. Collectively, these have led to a host of reproducible findings in other areas of medicine. In ASDs, the application of rigorous GWAS methodology has so far led to the identification of three disorder-associated alleles that meet accepted discovery criteria: one mapping to an intragenic region on chromosome 5p between the genes encoding the neuronal adhesion molecules Cadherin 9 (CDH9) and Cadherin 10 (CDH10) 45 , a second mapping within 80 kb of Semaphorin 5A (SEMA5A) 46 , and a third mapping in the locus encoding the MACROD2 gene 47 . However, despite justifiable excitement over the emergence of alleles demonstrating genome-wide significance and surviving internal replication before publication, there remain important uncertainties; each study has so far failed to replicate the findings from either of the others and a joint evaluation of all three investigations has suggested that the combined data decreases the evidence for association for all of the identified risk alleles 41 . As noted above, it seems likely that sample sizes in ASDs are still considerably underpowered. And although it is certainly possible that common alleles will not be found to contribute to ASD risk, given recent findings, particularly with regard to schizophrenia 41 , it seems far more likely that there are indeed multiple common variants of very small effect remaining to be identified.
When such alleles are definitively replicated, translating the initial mapping into potentially targetable neurobiological mechanism will constitute an additional challenge. Through 'guilt by proximity' , those nearest to the current GWAS alleles have tended to be characterized as new risk genes. However, this short hand may obscure a much more complex situation. For instance, the 5p common variant 45 noted above mapped between two molecules that are implicated in histogenic neural events, but resides approximately 1 Mb from either gene and is not in strong linkage disequilibrium with these Cadherin loci. This highlights several pressing questions that arise subsequent to an initial GWAS finding, regardless of whether an allele is found in coding, intra-or intergenic regions, that must be answered experimentally: whether nearby transcript(s) exhibit disorder-related alterations in expression or function, whether there may be other cryptic proteincoding or other transcripts in association intervals that may prove relevant biologically, and, for noncoding changes, how alterations in gene regulation relate to neural processes underlying ASDs. In this context, the small overall increment in genetic risk associated with the vast majority of alleles identified so far by GWAS, including with regard to ASDs, suggests that observable effects in experimental assays also could be quite modest.
Nonetheless, in our view, it would be a mistake to equate the importance of a common variant finding with its effect size, just as it would be short-sighted to judge the effect of a rare variant finding on the overall frequency of the mutation in the general population. Both approaches, when successful, provide important avenues to illuminate the etiology, molecular and cellular biology, and genetic architecture of ASDs.
Rare variation. Although the emphasis on the contribution of rare variation has grown of late, there is in fact a comparatively long history in ASDs. For example, studies of Mendelian single-gene disorders over the past decade have offered key insights into the molecular r e v i e w mechanisms of cognitive and behavioral syndromes and have already extended into the realm of social disability. Several such disorders, best exemplified with regard to fragile X and tuberous sclerosis 48 , demonstrate a clear increase in risk for ASDs. Moreover, syndromedefining mutations have frequently been found in probands previously diagnosed with idiopathic ASDs. These observations suggest that the illumination of underlying neurobiological mechanisms will have implications that are likely to extend beyond the confines of the syndromes themselves. This is not to suggest that there is unanimity with regard to the value of studying the coincidence of ASD and known genetic disorders. The findings of subtle differences in the social phenotypes relative to idiopathic autism and the observation of a correlation between lower IQ and the diagnosis of autistic features 48, 49 has led to some skepticism that studying known single-gene disorders will translate into an improved understanding of 'pure' social disability 49 .
However, as the molecular underpinnings of these syndromes have been elaborated, they have tended to converge on alterations in the assembly and functioning of synapses 33, 50 , and these discoveries have been markedly consistent with the earliest molecular genetic findings in studies of idiopathic ASDs. For instance, in 2004, Neuroligin 4 (NLGN4), which encodes a neuronal adhesion molecule present in the postsynaptic density of excitatory synapses, was the first transcript for which rare coding ASD-related mutations were identified in nonsyndromic individuals 16, 51 . Subsequent studies have reproducibly identified rare functional mutations (both sequence and structural) in the genes encoding Neurexin 1 (NRXN1) 18,52-54 , a presynaptic binding partner for NLGNs, as well as SHANK3 (SHANK3) 22, 55 and, more recently, SHANK2 (SHANK2) 56, 57 , postsynaptic scaffolding molecules that interact with PSD95.
The convergence of data from studies of rare variation in syndromic and idiopathic ASDs is similarly reflected in recent findings with regard to Contactin and associated molecules. Contactin 4 (CNTN4) was first identified as having a role in social and intellectual disability in the context of studies of a recurrent deletion syndrome 58, 59 , and heterozygous mutations have subsequently been identified in well-characterized individuals with idiopathic ASDs 60, 61 . Similarly, very rare homozygous protein-truncating mutations in CNTNAP2 have been described in consanguineous pedigrees demonstrating intractable epilepsy and ASDs 62 , and heterozygous rare mutations have been found in individuals with idiopathic social disability 17, 26, 63 and schizophrenia 64 . Common variants in CNTNAP2 have been associated with ASDs and language delay 26, 65 , as well as altered functional connectivity 66 , selective mutism and anxiety 67 .
These data point to a promising area of investigation and underscore key challenges in elaborating mechanism in the absence of definitive human genetic findings. For example, there are several lines of evidence for the involvement of CNTNAP2 in idiopathic ASDs, but neither a strict replication of a common associated allele nor consistent statistical evidence for an excess burden of rare variants has so far materialized. In addition, hypotheses regarding the underlying histogenic disruptions relevant to ASDs are just beginning to emerge. In the case of FMRP and NLGN4 and related molecules, the issues of specificity, location and timing of dysfunction, and their relationship to phenotype remain something of a puzzle. Even less is known about the normal functions of CNTNAP2 in the brain. However, the rare opportunity to examine pathological specimens from human temporal lobe resections 62 in consanguineous families with epilepsy, ASDs and loss-of-function mutations in CNTNAP2 pointed to abnormalities in cortical neuronal morphology and migration. Whether these reflect an alternative pathway to ASDs or these mutations simultaneously lead to disruptions in the formation and/or functioning of excitatory and glutamatergic synapses remains to be elucidated.
Arguably the most important recent milestone in the study of rare variation in ASDs has been the emergence of copy number variation analyses, affording the first opportunity to conduct unbiased surveys for rare variation across the genome at submicroscopic resolution. The first such analyses demonstrated that rare de novo structural variations were overrepresented in simplex families (those with only one affected offspring), as compared with both controls and families in which there were multiple affected individuals 17 . This excess of de novo CNVs in cases versus controls has now been repeatedly replicated 18, 61, 68 , but it is not as clear yet whether there is a substantial difference in the contribution of these events in simplex versus multiplex ASDs 57 .
Studies of increasingly large samples have delved more deeply into the relationship of de novo CNVs and ASD risk. For example, two recent independent analyses of a comprehensively assessed simplex cohort, the Simons simplex collection, involving more than 1,000 families and including unaffected siblings, demonstrated that the risk attributable to individually rare de novo CNVs encompassing multiple genes is many times greater than the effect sizes suggested for any common ASD variant, with odds ratios of ~5-6 (refs. 20,21) .
It is noteworthy that, although the resolution of detection of array platforms has increased markedly over the last several years, the overall burden of these de novo variants in ASD populations has remained fairly constant, with between 5-10% of affected individuals in simplex families carrying at least one de novo CNV. On the basis of recent data, it would seem that ASD risk is most pronounced (or detectable) for large (>100 kb) multigenic de novo CNVs. Whether this is a consequence of such events covering more genomic territory and thus being more likely to disrupt a single gene of particular relevance, or whether, as we suspect, it suggests that the simultaneous disruption of multiple genes and regulatory elements in genomic intervals carries particular risk remains to be clarified.
Several studies also have identified and replicated specific recurrent structural variations that are strongly associated with ASDs. A cumulative analysis of confirmed de novo variants reported across four large genome-wide case-control studies demonstrated that deletions and duplications at 16p11.2 (when considered either independently or combined), duplications at 15q11-13, deletions and duplications combined at 22q11.2, deletions at the Neurexin 1 locus, and duplications at 7q11.23 all reach genome-wide significance 21 . Multiple additional intervals, involving both recurrent rare de novo and transmitted CNVs, including those at 17q12 (ref. 69 ) and 1q21 (ref. 70) , have been observed to be over-represented in cases compared with controls and, with the additional power afforded by larger samples, appear to be poised to cross this threshold as well. Along these lines, another recent large-scale study looking both at transmitted and de novo CNVs noted that the former also contribute to ASD risk, but with an overall effect that is somewhat more attenuated than for de novo CNVs alone 68 .
Several recent specific findings are particularly notable. 16p11.2 (refs. [17] [18] [19] 71 ) and 15q11-13 CNVs are currently the most frequently seen in idiopathic ASDs, with deletions and duplications of the former identified cumulatively in ~1% of cases. Moreover, the finding that both deletions and duplications at 16p11.2 are independently associated with ASDs is striking. It was not at all clear initially that both increases and decreases in copy number (and presumably in gene dosage) at a single locus should account for similar phenotypes. In the case of 16p11.2, the additional observation that duplications carry somewhat smaller risk for ASDs than deletions, but then also increase the liability for schizophrenia, is similarly quite intriguing. r e v i e w Finally, the diversity of possible outcomes of reciprocal changes in copy number is underscored by the recent association of duplications at 7q11.23. Deletions of this interval result in Williams-Beuren syndrome, characterized, in part, by a social, highly affiliative and empathic personality 72 . This contrast with ASDs suggests that a dosage-sensitive gene or genes, most likely mapping within this region, is critical for the modulation of human social behavior.
Finally, two recent copy number variation analyses have used the observations of the frequency and distribution of de novo events to estimate the likely number of such loci contributing to ASDs 20, 21 . Both arrived, via independent methods, at ~300 ASD-related rare de novo risk CNV regions in the human genome, providing additional strong evidence of locus heterogeneity in ASDs and highlighting the opportunities for discovery that remain in the study of rare structural variation.
As with every other area of inquiry related to ASDs, however, the next steps are likely to confront considerable obstacles. The replication of risk regions is a cause for celebration in the psychiatric genetics community, but the requirement to move from the identification of an associated region to a risk gene or genes is pressing. The tendency for the identified de novo CNVs to be large and encompass many genes, coupled with recent evidence supporting a multiple rare hit mechanism 70 , suggests that there is considerable work to be done to further clarify the neurobiological substrates of these reproducible genomic findings.
Further challenges in demonstrating and clarifying risk
It is axiomatic that the stronger the genetic evidence relating a variation to a clinical outcome, the more robust will be the conclusions that emerge from subsequent neurobiological studies. In turn, these discoveries will offer the possibility of providing the necessary traction to undertake translation to the clinic. Consequently, it is worth considering the challenges that remain, in light of recent findings, in establishing a clear relationship between genotype and phenotype and to anticipate how these obstacles are likely to play out with the advent of next generation sequencing.
Risk versus causal alleles. Recent success in rare variant discovery has, along with recent GWAS results, forced a re-examination of long-held views regarding the manner in which specific classes of variation contribute to pathology (Fig. 1) and, consequently, how such a relationship may be established. For instance, the expectation that rare, functionally deleterious disease alleles of large effect will show a 1:1 correspondence (or nearly so) with a given phenotype has been repeatedly challenged. For example, with regard to 16p11.2, risk CNVs have often not been found among affected first degree relatives in nuclear families and, conversely, have been present in unaffected family members 18, 19, 73 . A cursory look at these pedigrees would tend to argue against the relevance of these variants on the basis of Mendelian expectations. In contrast, the strength of the replicated population association underscores the importance of rethinking notions of causality and risk for rare variants in ASDs.
Along similar lines, as common alleles have been found to carry much smaller risks than anticipated, the range of plausible effect sizes attributable to rare and very rare alleles has necessarily expanded. As a consequence, investigators are increasingly required to demonstrate risk probabilities for rare alleles that are neither necessary nor sufficient to lead to the phenotype (Fig. 1) . In this regard, for both common and rare variant studies, the importance of stringent statistical thresholds, control for known confounds (including population stratification, technical artifact and multiple comparisons) and independent replication cannot be overstated. Moreover, despite recent successes with regard to CNVs, it is important to recall that, although effect sizes are considerably larger than those thought plausible for common variant, the low frequency of the events in question demand that discovery efforts rely on very large samples, rivaling those required for association of common alleles. Finally, next generation sequencing has highlighted the substantial number of disease-neutral rare singlenucleotide variants (SNVs) present in each individual genome. Difficulties in distinguishing these from the functional SNVs of interest, further complicates discovery efforts. In fact, studies in other areas of medicine have suggested that it may require specific knowledge of the protein in question to identify true disease associations 74 .
These considerations cumulatively point to important challenges for the analysis of whole-exome and whole-genome sequencing data. Indeed, even in the case of SNVs carrying relatively large effects and using so-called collapsing methods that tally rare sequence variants in a gene unit, initial genome-wide case-control studies of SNVs may well not be sufficiently well-powered to drive initial gene discovery efforts genome wide.
Alternative strategies are already being explored. For example, in contrast with rare transmitted SNVs that are quite numerous, rare coding de novo missense and nonsense single-nucleotide changes are seen infrequently, occurring at less than once per exome per parent-child trio. Consequently, the observation of multiple recurrences among independent cases at a single gene is very unlikely to be a chance event. We exploited similar properties with regard to recurrent de novo structural variation in ASDs to generate sufficient power from a sample of approximately 1,000 cases and 1,000 controls to exceed a rigorous genome-wide significance threshold for CNVs 21 carrying moderate-tolarge effects. Similar approaches may prove to be extremely useful with regard to exome-wide and genome-wide sequence analyses. Moreover, once a potential sentinel event is identified, the ability to investigate in a targeted way rare transmitted and de novo SNVs in a specific transcript in many tens of thousands of individuals is now plausible as a result of the rapidly declining costs of next-generation sequencing.
Phenotypic specificity. Another source of complexity in establishing the relationship between genetic variation and psychiatric disorder derives from the recent observations that identical mutations may be associated with highly divergent clinical phenomena. Again, 16p11.2 is a case in point. Deletions at this locus have been strongly associated with ASDs, intellectual disability and obesity 75 , whereas duplications at this region have been convincingly shown to be associated with a wide range of behavioral phenotypes, including ASDs and schizophrenia 44 , and perhaps attention deficit disorder and bipolar disorder as well 19 .
It is worth considering the range of plausible explanations for these and similar findings. First, they could simply reflect differences in labeling. For example, social impairment could be defined in one study as an ASD, and as schizophrenia prodrome or negative symptoms in another. Second, they may reflect the contribution of age-dependent penetrance. If children with ASDs are also at higher risk for later developing psychotic symptoms, their ascertainment at an early age would yield evidence for association with the former, whereas ascertainment in adulthood would indicate association with the latter. Third, these could reflect epiphenomena, resulting from individuals with intellectual impairment having impaired ability to compensate for limitations in, for instance, social functioning. On the basis of this view, gene discovery in cohorts that have both intellectual disability and ASDs would be more likely to identify highly penetrant alleles and molecular mechanisms that are relevant to the former, rather than clarifying the latter 49 . Fourth, these could be mediated through apparently identical, but functionally distinct, alleles; for example, r e v i e w having gain-of-function versus loss-of-function point mutations at a single locus or, alternatively, reflecting epigenetic phenomena, as is the case with regard to 15q11-q13 deletions leading alternatively to Angelman or Prader Willi syndromes. Fifth, these could reflect the involvement of shared behavioral endophenotypes among distinct disorders, for example language functioning or attention; and, finally, type 1 error combined with publication bias must be considered.
All of these explanations are reasonable, but none convincingly account for the entirety of recent observations. For example, although distinguishing ASD and schizophrenia may be difficult in some cases, their natural histories are markedly different in most, making it unlikely that diagnostic substitution would be sufficiently common to explain the observed overlap. Similarly, although there are certainly cases in which children with ASDs go on to develop psychosis in adulthood, review of the longitudinal data, although limited, does not suggested a substantial increase in risk for psychotic illness in adulthood among children presenting initially with ASDs 76 . Notably, given the number of regions that have been found to carry risks for both, these questions may now be evaluated directly via prospective longitudinal studies of genetically homogenous subjects.
Recent data should also temper arguments that studies of rare mutations are likely to find ID genes, with ASDs appearing as a secondary phenomenon. For instance, although large de novo CNVs carry marked risks for an ASD diagnosis, we found that they correlate very modestly with lower IQ in males and show no such effect in females in the Simons simplex collection 21 . The converse was also true: lower IQ served as a poor predictor for an individual carrying an ASD de novo risk CNV. These findings, which are consistent with a recent population-based twin study that found only a modest correlation of autistic traits and lower IQ 77 , suggest that the co-occurrence of ID and ASDs does not necessarily imply a predominant biological role for the former.
A final and, we think important, possibility is that the divergent phenotypes emerging from identical genetic variation(s) are a consequence of the combination of pleiotropy and locus heterogeneity (Fig. 2) . As considered in more detail below, this model would suggest that mutation(s) at hundreds of targets could converge on a much smaller number of molecular, cellular and anatomical pathways that are critical to the development and function of the CNS. Subtle alterations in these basic processes would then set the stage for developmental trajectories that could encompass a wide array of behavioral, emotional and social phenomena. The emergence of a complex behavioral phenotype would consequently be influenced by multiple inputs (not addressed in detail here) beyond the initial genetic insult, including environmental factors, epigenetic mechanisms, stochastic events and additional genetic variations, either in the form of multiple rare alleles or additional modulatory common variants.
What is clear at present is that the field has not yet arrived at a new coherent understanding of the relationship of genotype and phenotype in ASDs. The observations of profound genetic heterogeneity present a clear contrast to the coherence of ASDs observed at the phenomenological and clinical level, as exemplified in replicable neuroimaging, eye-tracking and other neuropsychological findings across patient cohorts. The next big hurdle, in the wake of the current exciting era of gene discovery, will be to not only clarify how identical risks emerge as distinct phenomena, but to integrate this understanding into the development of new therapeutics and the reconceptualization of approaches to psychiatric diagnosis.
Top down versus bottom up: the hard work of next steps Given the sheer amount of genomic, transcriptomic and proteomic data already available, combined with an ever-increasing, detailed understanding of the organization of local and long distance circuits involved in higher social-emotional and cognitive processes, the task of extending beyond correlational relationships in childhoodonset neurodevelopmental disorders is daunting. Studies that delve deeply into single risk factors currently remain the most tractable for investigators. However, these require more than the observation of a genetic variation accompanied by a descriptive analysis of behavioral outcomes. Risk must be connected to specific neurodevelopmental phenomena to make findings relevant and translatable.
However, given that there are literally thousands of genes involved in the histogenic processes of neuronal and glial specialization, migration, axon targeting, synaptogenesis, and activity-dependent Figure 2 Convergent rare risks and common modulators leading to divergent neuropsychiatric disorders. The figure illustrates one explanatory model for the combination of specific rare variations, carrying large effects for ASDs, with common functional variants modulating the risk for clinically distinct phenomena. The ideogram on the left represents the human genome, the black bars indicate the high degree of locus heterogeneity underlying ASD, and the dashed lines link divergent loci to rare mutations that disrupt protein function and/or structure and subserve coherent molecular pathways. Here this is illustrated as multiple mutations in synaptic molecules, although, as noted in the text, it is likely that a variety of distinct neural-developmental processes are altered by ASD-related mutations. In this model, alterations to basic cellular and molecular processes are expressed through increasingly complex layers of organization, represented in the figure by the diffusion tensor imaging data showing long-range neural pathways. Moreover, the manifestations of these altered molecular and cellular processes play out across development and are influenced by a variety of factors, including common functional genetic variation (most likely regulatory in nature), stochastic effects, environmental inputs and epigenetic phenomena. The graph on the far right further illustrates that particular genetic variations may launch and simultaneously influence diverse developmental trajectories (lines of similar colors reflect rare mutations in the same CNV or gene) that may ultimately correspond to a range of distinct clinical phenomena (in this example, ASDs and schizophrenia (Scz)) or to typical development. r e v i e w stabilization and pruning, the classic bottom-up approach for deciphering the involvement of disease-relevant genes in clinical populations is not without its difficulties. Confidently assigning a phenotypic dimension to a single gene, which may encode multiple protein isoforms and underpin multiple highly complex functions at different times in development, may in some cases prove an intractable problem. Even in syndromic disorders, there have proven to be substantial challenges to defining genotype-phenotype relationships. For example, in the case of Rett syndrome, mosaicism of X inactivation, multiple and distinct mutations 78 , and likely other genetic and epigenetic modifiers appear to contribute to a variable relationship between mutation and clinical presentation. It is consequently reassuring then to note that progress is being made in syndromic disorders that have well-delineated genetic causes, such as fragile X, tuberous sclerosis or Rett syndromes 79, 80 , with findings leading to new therapeutic strategies that are being translated into clinical trials 81 . These suggest that a somewhat reductionist approach, in the face of all the aforementioned complexity, can still be productive.
However, with regard to complex multigenic disorders, these types of investigation will undoubtedly need to be complemented by topdown approaches that begin to elaborate the combinatorial nature of risk. For instance, recent studies of FOXP2 have identified this protein as a clear transcriptional regulatory hub influencing three implicated genes, CNTNAP2 (ref. 82) , MET 83 and PLAUR 84 , providing the potential for synthetic investigations of ASD risk that might otherwise have been missed. Systems biological approaches are already being applied to genes in de novo CNVs 85 and differential gene expression in postmortem brain 40 in an effort to identify relevant molecular and neural networks and the nature of associated pathological changes. Clearly, it will be the integration of foundational neurobiological knowledge, combined with replicable genetic and genomic findings, and multidisciplinary and computational approaches [86] [87] [88] , that will ultimately illuminate the pathophysiology of ASDs.
